From @morgans following the Resmed (RMD) result on Friday: Resmed (RMD, Hold, Price Target A$5.40) - 2QFY14 earnings were below expectations as volumes and...

From @morgans following the Resmed (RMD) result on Friday: Resmed (RMD, Hold, Price Target A$5.40) - 2QFY14 earnings were below expectations as volumes and pricing continue to be affected by competition and US distributor distractions due to competitive bidding. While we continue to see offsets and remain optimistic of long-term growth prospects, the short/medium-term trajectory is uncertain. We lower our FY14-16F NPAT between 1.6-2.0%, on softer sales somewhat offset by margin support. With US dynamics remaining in flux and continued risk around competition, volatility is likely to remain. We lower our DCF/PE/SOP-based target price to A$5.40 and move to Hold pending greater visibility.


2 topics

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.